Klee Justin's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 373,295 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Justin B. Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 373,295 | 373,295 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin B. Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 248,865 | 3,583,481 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin B. Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.47 per share. | 02 Mar 2026 | 29,282 | 3,334,616 | - | 14.5 | 423,760 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.69 per share. | 02 Feb 2026 | 15,500 | 3,363,898 | - | 14.7 | 227,618 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 197,153 | 3,514,739 | - | 7.6 | 1,492,448 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 197,153 | 2,847 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.58 per share. | 15 Jan 2026 | 136,193 | 3,378,546 | - | 13.6 | 1,849,869 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 2,847 | 3,381,393 | - | 7.6 | 21,552 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 2,847 | 0 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 15 Jan 2026 | 1,995 | 3,379,398 | - | 13.9 | 27,701 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.09 per share. | 06 Jan 2026 | 7,715 | 3,317,586 | - | 11.1 | 85,589 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.37 per share. | 30 Sep 2025 | 29,775 | 3,325,501 | - | 14.4 | 427,950 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 30 Sep 2025 | 200 | 3,325,301 | - | 15.0 | 3,002 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.46 per share. | 31 Mar 2025 | 21,490 | 3,355,276 | - | 3.5 | 74,454 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 270,177 | 270,177 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 180,118 | 3,376,766 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 03 Mar 2025 | 4,595 | 3,196,648 | - | 3.2 | 14,483 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 36,310 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 05 Feb 2025 | 36,310 | 3,201,243 | - | 1.6 | 57,007 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Feb 2025 | 11,855 | 3,164,933 | - | 3.5 | 41,104 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 06 Jan 2025 | 7,471 | 3,176,788 | - | 4.0 | 30,202 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 63,690 | 36,310 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 04 Nov 2024 | 63,690 | 3,184,259 | - | 1.6 | 99,993 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 18,589 | 3,120,569 | - | 3.2 | 59,429 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 179,850 | 3,139,158 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 4,135 | 2,959,308 | - | 18.7 | 77,440 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Klee Justin | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 126,667 | 2,963,443 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Klee Justin | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 5,841 | 2,836,776 | - | 16.3 | 95,372 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 16 Mar 2023 | 96,555 | 2,796,062 | - | 31.8 | 3,074,359 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 50,000 | 2,842,617 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.48 per share. | 16 Mar 2023 | 3,445 | 2,792,617 | - | 32.5 | 111,877 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 4,122 | 2,894,463 | - | 36.1 | 148,717 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 1,846 | 2,892,617 | - | 36.8 | 67,912 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 05 May 2022 | 334,520 | 2,898,585 | - | 0.4 | 123,772 | Common Stock |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 334,520 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 75,000 | 2,564,065 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 0 | - | - | Series C-1 Preferred Stock | ||
| Amylyx Pharma Inc | Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 2,489,065 | - | 0 | Common Stock |